Trientine - Protemix

Drug Profile

Trientine - Protemix

Alternative Names: GC 811007; Laszarin; PX 811019

Latest Information Update: 28 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Protemix Corporation
  • Class Ethylenediamines; Small molecules
  • Mechanism of Action Chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus
  • Discontinued Diabetic cardiomyopathy

Most Recent Events

  • 20 Jun 2016 Protemix Corporation completes a phase II trial in Non-diabetic Subjects and Type 2 Diabetes Mellitus in New Zealand before February 24, 2012 (ACTRN12612000261819)
  • 24 Feb 2012 Phase-II clinical trials in Type-2 diabetes mellitus in New Zealand (PO)
  • 30 Jun 2010 Discontinued - Phase-II for Diabetic cardiomyopathy in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top